Small Cell Lung Cancer | Clinical

Real-World Implications of the IMpower133 Trial in ES-SCLC

June 28, 2022

Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.